Recrutamento encerrado
FASE
Número Europeu 2017-003295-31
C3441021 TALAPRO-2
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Detalhes
Destaques